StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
003017.SZ$27.69-1.77%
Fair $27.69+0.0%

003017.SZ

Zhe Jiang Dayang Biotech Group Co., Ltd.

Basic Materials / ChemicalsShenzhen

$27.69

-0.50 (-1.77%)

Fairly Valued+0.0%Fair Value $27.69Fund rank 27/100 · Data gapFallback financials|
SA 46/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $78.8M · quality 45.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 21/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · 003017.SZLocal privado en este navegador · Zhe Jiang Dayang Biotech Group Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.3B

P/E

22.5x

↑

EV/EBITDA

12.0x

↑

ROE

8.8%

↑

Gross Margin

22.9%

↑

Debt/Equity

0.32

↑
52-Week Range$28
$24$38

TradingView lightweight chart

003017.SZ price, volumen y niveles de valoración

Último $27.69Periodo -6.7%
Fair value: $27.69

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-0.4%

FCF CAGR

—

FCF margin

8.0%

FCF / Net income

0.84x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.05B · net income $99.9M · FCF $83.7M

2022-FY → 2025-FY

Gross margin

22.9%+9.1% pts

Operating margin

11.8%+6.4% pts

Net margin

9.6%+1.9% pts

FCF margin

8.0%+9.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.05B$1.05B$910.0M$919.5M$1.06B
Net Income$99.9M$99.9M$63.7M$50.0M$80.7M
EBITDA$183.7M$183.7M$147.1M$122.8M$123.2M
EPS1.211.210.780.621.39
Gross Margin22.9%22.9%19.6%18.1%13.8%
Operating Margin11.8%11.8%8.9%6.8%5.4%
Net Margin9.6%9.6%7.0%5.4%7.6%
Balance Sheet
Debt/Equity0.320.320.350.250.29
Current Ratio1.231.23———
Cash Flow
Free Cash Flow$83.7M$83.7M$2.7M$78.8M$-12.8M
Returns
ROE8.8%8.8%6.1%5.0%8.2%
Valuation
P/E22.5122.5122.6538.2014.64
EV/EBITDA12.0012.009.9114.4810.82
P/B2.012.011.371.891.20
Growth & Yield
Revenue Growth14.9%14.9%-1.0%-13.1%—
EPS Growth56.2%56.2%25.4%-55.3%—
Dividend Yield2.1%2.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

26.5%

muy exigente

EPS terminal req.

$2.46

Spread vs growth

29.7%

5Y implied EPS CAGR

19.6%

exigente

EPS terminal req.

$2.97

Spread vs growth

36.5%

10Y implied EPS CAGR

14.7%

razonable

EPS terminal req.

$4.79

Spread vs growth

41.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +12.7%

Total return

+12.7%

Start / end P/E

32.2x → 22.8x

EPS bridge

0.78 → 1.21

Residual

-16.4%

EPS growth+56.2%
Multiple rerating-29.2%
Dividend+2.1%
Residual / FX / buybacks / cross-term-16.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.